\n\n\n\n\t\t\n\t\t\teGeen\n\t\t\thttp://www.egeeninc.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tEGeen is an integrated pharmacogenetics company using the analysis of disease and drug response data in association with DNA and biomarker profiles emerging from the Estonian Genome Project (EGP)....More»
\n\t\t\tEGeen is an integrated pharmacogenetics company using the analysis of disease and drug response data in association with DNA and biomarker profiles emerging from the Estonian Genome Project (EGP). EGeen develops pharmacogenetics-based tests to identify new uses for existing drugs, to improve drug safety and to facilitate new drug development.EGeen\'s unique key asset is its twenty-five year exclusive license for commercial use of all data emerging from the Estonian Genome Project (EGP), closely associated with the national healthcare system of Estonia that covers the entire population. EGeen has a unique longitudinal access to DNA, biomarker and tissue samples of the globally applicable population, accompanied by high-quality medical records prepared by primary physicians and specialists. EGeen has established extensive platforms for bioinformatics, genotyping and other screening assays, in addition a well-organized clinical trial capability.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tMountain View, CA, United States\n
\n\t\t\t\tIndustry: Biopharmaceuticals
\n\t\t\t\tTags:\n\t\t\t\tbiotech,\n\t\t\t\tintegrated pharmacogenetics,\n\t\t\t\tDNA,\n\t\t\t\tEGP,\n\t\t\t\tbiomarker,\n\t\t\t\tdrug,\n\t\t\t\tdiseas,\n\t\t\t\tEGeen\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series A - $4.2M (11/02/2002)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tBaltics Small Equity,\n\t\t\t\t\t\n\t\tBiotech Technology Ventures,\n\t\t\t\t\t\n\t\tDFJ,\n\t\t\t\t\t\n\t\tSmall Enterprise Assistence Fund\n\t\t\t\t
\n\t\t\t